Iorio, Marianna
Davatgarbenam, Sahar
Serina, Stefania
Criscenzo, Paolo
Zdouc, Mitja M.
Simone, Matteo
Maffioli, Sonia I.
Ebright, Richard H.
Donadio, Stefano
Sosio, Margherita
Funding for this research was provided by:
Regione Lombardia and Italian Ministry of Research (30190679, DM60066)
European Union’s Horizon 2020 research and innovation program under grant agreement (721484)
NIH (GM041376, AI104660)
Article History
Received: 7 December 2020
Accepted: 18 February 2021
First Online: 12 March 2021
Competing interests
: M.I., S.S., M. Simone, S.I.M., S.Donadio and M. Sosio, are employees and/or shareholders of NAICONS, which owns IP for pseudouridimycin. The authors declare no competing interests.